These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37781802)

  • 41. Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study.
    Kwon HS; Park Y; Kim JH; Kim SH; Jun JB; Park S; Kang DR; Choi H
    Neurol Sci; 2023 Feb; 44(2):593-600. PubMed ID: 36271260
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Allopurinol efficacy in patients with tophus gout and chronic renal failure].
    Iakunina IA; Barskova VG; Nasonova VA
    Ter Arkh; 2006; 78(6):88-91. PubMed ID: 16881370
    [No Abstract]   [Full Text] [Related]  

  • 43. Clinical practice. Gout.
    Neogi T
    N Engl J Med; 2011 Feb; 364(5):443-52. PubMed ID: 21288096
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database.
    Ito S; Torii T; Nakajima A; Iijima T; Murano H; Horiuchi H; Yamanaka H; Honda M
    BMC Pediatr; 2020 Oct; 20(1):481. PubMed ID: 33059648
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Burden and management of gout in a multi-ethnic Asian cohort.
    Chua CKT; Cheung PP; Santosa A; Lim AYN; Teng GG
    Rheumatol Int; 2020 Jul; 40(7):1029-1035. PubMed ID: 31758246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data.
    Akari S; Nakamura T; Furusawa K; Miyazaki Y; Kario K
    J Clin Hypertens (Greenwich); 2022 Aug; 24(8):1068-1075. PubMed ID: 35818841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Febuxostat for prevention of gout attacks.
    Pohar S; Murphy G
    Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperuricemia, Gout, and the Brain-an Update.
    Latourte A; Dumurgier J; Paquet C; Richette P
    Curr Rheumatol Rep; 2021 Dec; 23(12):82. PubMed ID: 34971414
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.
    Ting K; Gill TK; Keen H; Tucker GR; Hill CL
    Intern Med J; 2016 May; 46(5):566-73. PubMed ID: 26765205
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
    Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy].
    Eliseev MS; Novikova AM
    Ter Arkh; 2019 May; 91(5):120-128. PubMed ID: 32598686
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment.
    Stamp LK; O'Donnell JL; Zhang M; James J; Frampton C; Barclay ML; Chapman PT
    Arthritis Rheum; 2011 Feb; 63(2):412-21. PubMed ID: 21279998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preservation of renal function during gout treatment with febuxostat: a quantitative study.
    Whelton A; MacDonald PA; Chefo S; Gunawardhana L
    Postgrad Med; 2013 Jan; 125(1):106-14. PubMed ID: 23391676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Update on gout and hyperuricemia.
    Baker JF; Schumacher HR
    Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Associations of hyperuricemia, gout, and UA-lowering therapy with the risk of fractures: A meta-analysis of observational studies.
    Zong Q; Hu Y; Zhang Q; Zhang X; Huang J; Wang T
    Joint Bone Spine; 2019 Jul; 86(4):419-427. PubMed ID: 30910706
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CaseBook challenges: Managing gout, hyperuricemia and comorbidities -- dialogue with the experts.
    Bakris GL; Doghramji PP; Keenan RT; Silber SH
    Am J Med; 2014 Jan; 127(1):S1. PubMed ID: 24268074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urate-lowering therapy may mitigate the risks of hospitalized stroke and mortality in patients with gout.
    Yen FS; Hsu CC; Li HL; Wei JC; Hwu CM
    PLoS One; 2020; 15(6):e0234909. PubMed ID: 32574194
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan.
    Hakoda M; Kasagi F
    Mod Rheumatol; 2019 Sep; 29(5):880-884. PubMed ID: 30175646
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.